RepliCel Sells Assets and Licenses Patents for Shareholder Gain
Company Announcements

RepliCel Sells Assets and Licenses Patents for Shareholder Gain

Story Highlights

RepliCel Life Sciences (TSE:RP) has released an update.

RepliCel Life Sciences has announced the sale of its assets and licensing of patent rights to 1456390 B.C. Ltd, a company controlled by RepliCel’s CEO Andrew Schutte. The deal is seen as the best path forward for maximizing shareholder return and commercializing the assets. The agreement includes an 8% royalty on gross profits from the commercialized products, promising a potential value increase for shareholders.

For further insights into TSE:RP stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskRepliCel Secures Million Dollar CEO-Backed Loan
TipRanks Auto-Generated NewsdeskRepliCel Proposes Asset Sale to Secure Future Royalties
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App